Generics in antiviral market are forecast to grow at a CAGR of 10.5% during 2010-2018, largely due to series of patent expiries in the antiviral market.
(PRWEB) February 14, 2013
Generics in global antivirals market are estimated to be $4.2 billion in 2010 and are forecast to grow at a CAGR of 10.5% and reach $9.2 billion by 2018. From 2004, the market grew at a CAGR of 21.1% to reach $4.2 billion in 2010. Global generic antiviral market is comprised of revenues generated by various generic antiviral drugs. In 2010, it is estimated that generics in HIV market accounted for largest market share in total generic antivirals market. Generics in HIV market accounted for 46% of market share in total generic antivirals market in 2010, while generic herpes therapeutics accounted for 39.6% of market share. Generic influenza therapeutics accounted for 1% of total market share. Generic CMV market holds about 9.6% of share in total antiviral generic market, while generic hepatitis market accounted for only 3.9% of market share.
Series of patent expiries of key antiviral drugs will positively impact the market. Increase in patient population, reforms in government policies towards the use of generic drugs could be other major drivers of the market during the forecast period.
The report covers antiviral therapeutics including HIV therapeutics, Hepatitis therapeutics, Herpes therapeutics, CMV therapeutics and Influenza therapeutics.
The report provides data and analysis on the global generics in antivirals market, market forecasts for the global generics in antivirals market until 2018, market data on geographical landscape including country wise coverage, cost of therapy, market size and market share, key drivers and restraints that have created significant impact on the market, an overview of the competitive landscape of the global generics in antivirals market including top companies profiles, key M&A activities and licensing agreements, that have taken place between 2007 and 2011 in the global generics in antivirals market.
Leading players featured in the report include Teva Pharmaceuticals, Aurobindo Pharma Ltd, Watson Pharmaceuticals and Mylan Inc.
For more information please visit http://www.researchandmarkets.com/research/hq8zbd/generics_in_the
Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716